Dr. Frédérique Vegran - immuno oncology - Best Researcher Award

INSERM - France

Author Profile

🎓 Early academic pursuits

Frédérique Vegran began her scientific journey with a strong foundation in cellular and molecular biology, earning her phd in this domain. during her early academic years, she exhibited a keen interest in understanding cellular behavior under varying physiological conditions. this led her to pursue advanced studies and training in belgium, where she spent three years as a post-doctoral researcher. her research during this time revolved around the tumor microenvironment, hypoxia, and metabolic regulation—areas that laid the groundwork for her future focus in immuno-oncology, a field now evolving alongside advancements in power electronics and biotechnology integration.

🧪 Professional endeavors

Currently a full-time research scientist at inserm umr1231 in dijon, france, frédérique vegran has established herself as a leading figure in immuno-oncology. her professional tenure is marked by active involvement in cutting-edge research aimed at enhancing anti-tumor immune responses. she has supervised multiple phd candidates and participated in thesis evaluation committees, highlighting her commitment to nurturing future generations of scientists. her involvement in research also bridges academic curiosity with translational potential—something akin to the precision and adaptability found in modern power electronics systems.

🔬 Contributions and research focus

Vegran’s groundbreaking contributions have significantly advanced our understanding of t cell biology in cancer. one of her landmark findings includes the role of il-1b in promoting the anti-tumor effect of th9 cells (nature immunology, 2013). she also revealed a novel transcriptional function of nlrp3 in th2 cells (nature immunology, 2015), and more recently, identified the immuno oncology regulatory role of nlrp3 in th17 differentiation and its acquisition of treg-like properties within tumor environments (cellular and molecular immunology, 2025). such insights have reinforced the importance of targeted immune modulation—an idea resonating with the fine-tuning concepts used in power electronics.

🌍 Impact and influence

Her influence extends beyond publications, with an h-index of 37 and i10 index of 52, demonstrating consistent citation and global recognition of her work. having authored over 67 peer- immuno oncology reviewed articles, including in top-tier journals, frédérique vegran continues to impact the scientific discourse in immuno-oncology. her discoveries have paved new avenues for therapeutic strategies, inspiring researchers globally to explore the interplay between immune cells and cancer. her professional memberships with the french society of immunology (sfi) and the french society for immunotherapy of cancer (fitc) further signify her standing in the field.

📊 Academic cites

Vegran’s academic output is notable with 67 journal publications indexed in scopus and sci, alongside 8 completed and 3 ongoing research projects. she has contributed to 3 immuno oncology consultancy/industry-related projects and has 2 patents published, highlighting her dual focus on innovation and application. although she has not authored books, her work stands as a valuable reference across the immunological and oncological academic landscapes.

🧬 Legacy and future contributions

Frédérique Vegran’s legacy lies in the transformative nature of her research on immune modulation in cancer. her consistent engagement in phd mentorship, cutting-edge experimentation, and scientific evaluation sets a strong example for academic leadership. looking ahead, her research is poised to further decode immune-cancer interactions, potentially contributing to the development of novel therapeutic interventions that integrate cellular biology with advanced technologies, much like how power electronics revolutionized modern engineering systems.

Notable Publications

Title: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Authors: P. Sonveaux, F. Végran, T. Schroeder, M.C. Wergin, J. Verrax, Z.N. Rabbani, ...
Journal: The Journal of Clinical Investigation
Title: Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis
Authors: F. Végran, R. Boidot, C. Michiels, P. Sonveaux, O. Feron
Journal: Cancer Research
Title: Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
Authors: M. Bruchard, G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, ...
Journal: Nature Medicine
Title: Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis
Authors: P. Sonveaux, T. Copetti, C.J. De Saedeleer, F. Vegran, J. Verrax, ...
Journal: PLOS ONE
Title: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation
Authors: M. Bruchard, C. Rebé, V. Derangère, D. Togbé, B. Ryffel, R. Boidot, ...
Journal: Nature Immunolog

Early academic pursuits 🎓

Dr. Zhen Yang embarked on a journey in the medical field with a focus on understanding complex biological systems. With a Doctor of Medicine degree, Zhen cultivated a deep interest in the mechanisms of diseases, particularly malignant tumors. This foundation laid the groundwork for a career dedicated to advancing medical science and improving therapeutic strategies.

Professional endeavors 🏢

Currently, Zhen serves as a postdoctoral research fellow and a distinguished research fellow, overseeing laboratory technicians and guiding research initiatives. Zhen has played a crucial role in leading significant projects, including the National Natural Science Foundation of China and key initiatives from the Tianjin Health and Education Commissions. These positions reflect Zhen's leadership and commitment to fostering innovative research environments.

Contributions and research focus 🔬

Zhen's research primarily centers on immunotherapy for malignant tumors, integrating Chinese and Western medicine approaches. This unique perspective aims to enhance treatment efficacy and patient outcomes. With over ten published papers in prestigious journals, including Oncology and immunity Autophagy, Cancer Letters, and International Journal of Biological Macromolecules, Zhen's work significantly contributes to the scientific understanding of immunotherapeutic strategies and their applications in clinical settings.

Accolades and recognition 🏅

Zhen's contributions to medical research have not gone unnoticed, with recognition from various academic bodies and funding agencies. Leading projects funded by the National Natural Science Foundation of China and receiving support from Tianjin’s health and education sectors Oncology and immunity underscores Zhen's influence and reputation within the scientific community. Zhen’s work has been pivotal in advancing research methodologies and clinical applications in immunotherapy.

Impact and influence 🌍

The impact of Zhen Yang's research extends beyond academic publications, influencing clinical practices and therapeutic strategies for treating malignant tumors. By bridging traditional and modern medicine, Zhen's work fosters a holistic approach to cancer treatment, potentially Oncology and immunity transforming how therapies are designed and implemented. Zhen’s research serves as a valuable resource for other scientists and clinicians in the field.

Legacy and future contributions 🔮

Dr. Zhen Yang's legacy is one of innovation and dedication to improving cancer therapies. As research in immunotherapy continues to evolve, Zhen is poised to make further significant contributions that could redefine treatment paradigms. The integration of traditional and modern practices in Zhen's work promises to open new avenues for research and clinical application, ensuring a lasting impact on future generations of medical professionals and researchers.